Ionis制药Eplontersen三期心脏转归试验至第140周未达主要终点

美股速递
Jul 09

Ionis Pharmaceuticals, Inc宣布,其针对药物Eplontersen开展的三期心脏转归临床试验“Cardio-Ttransform”,在截至第140周的分析中未能达到主要研究终点。

该试验旨在评估Eplontersen在特定患者群体中的心血管获益。尽管未能达到预设的主要终点,但公司表示,试验过程中收集到的全面数据正在进行深入分析,以评估药物的整体获益风险特征,并为未来的开发决策提供依据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10